Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by FredTheVoiceon Mar 15, 2018 3:07pm
110 Views
Post# 27722455

RE:RE:RE:RE:RE:RE:RE:RE:RE:Anonymus; thanks !

RE:RE:RE:RE:RE:RE:RE:RE:RE:Anonymus; thanks !
Palinc. You are questionning about volume. I made a little check up with the charts. Days like today I think are normal. Im not worried with a day with 200 000 shares that are traded. I dont think we will go back with a loads of day at 30 000 shares traded, the way it was pre-approval. My bet is that there will be in the next few months, solid days with some millions of shares changing hands. A lot of demand coming. So price going up.

Theres two major scenarios coming up, depending on the stategy of TH:

1. The company will let good news come in; first number of sales; demand for medication better than expected (or on the way to be), news on EUROPE approval (process), next quarter result.....
2. Like some folks suggest recently; another trading halt soon. And a decision by TH to annonce a bought deal financing at 10$;

That all depends on how advanced is the company with the dugs they want to buy........if its coming soon, than the second scenario is realistic. If not, than the first one.....because profits from TROGARZO will pay for the next drugs (2019?).

My confidence is with the directors of TH.

FTV.

Bullboard Posts